DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Continued Examination Under 37 CFR 1.114
A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on September 23, 2026, has been entered.
Acknowledgments
In the reply, filed on September 23, 2026, Applicant amended claims 1, 8, and 20-21.
In the final rejection of June 23, 2026, Examiner noted that the listing of references in the specification is not a proper information disclosure statement. Applicant argued: On pages 3-4 of the Action, the Examiner notes that U.S. Patent Application Publication No. 2016/0331951, cited in paragraph [0087] of the Specification, was not submitted in an Information Disclosure Statement and therefore not considered. Applicant respectfully directs the Examiner's attention to the IDS filed on 17 February 2024, in which Applicant cited U.S. Patent No. 10,549,084-the patent that issued from the application underlying U.S. Patent Application Publication No. 2016/0331951. The Examiner acknowledged this IDS on 18 December 2025 and indicated that U.S. Patent No. 10,549,084 had been reviewed and considered. Because the issued patent and the pre- grant publication derive from the same application, and the issued patent was properly identified by inventor, patent number, and issue date in accordance with 37 C.F.R. § 1.98(b)(1), Applicant has satisfied the disclosure requirement with respect to this reference. Citation of that U.S. Patent Application Publication No. 2016/0331951 would be redundant dn cumulative. Accordingly, Applicant respectfully requests that the Examiner reconsider this objection (Remarks, pages 7-8). Concern is withdrawn.
Examiner noted that the information disclosure statement filed January 21, 2023, fails to comply with 37 CFR 1.98(a)(3)(i). Applicant provided English translations for some, but not all, of the indicated foreign patent documents. Concern is maintained.
Examiner noted that the information disclosure statement filed February 17, 2024 (24 pages), fails to comply with 37 CFR 1.98(a)(2). Applicant provided copies of the indicated foreign patent documents. Concern is withdrawn.
Examiner noted that the information disclosure statement filed February 17, 2024 (40 pages), fails to comply with 37 CFR 1.98(a)(2). Applicant provided a copy of the indicated foreign patent document, and argued: On pages 4-5 of the Action, the Examiner states that a non-patent literature document 2 was not submitted with the IDS filed 17 February 2024. Applicant respectfully submits that this reference was in fact submitted, albeit with an incomplete and incorrect citation. In the IDS filed on 17 February 2024, Applicant cited the reference as "Angiography, Catheterization and Cardiovascular Diagnosis, Vol. 19. Pp. 123-128, 1990." Upon recognizing that the citation lacked certain identifying details, Applicant resubmitted the same document in the IDS filed on 10 April 2026, with the corrected and complete citation: Krieger, R. A., "CO2-Power-Assisted Hand-Held Syringe: Better Visualization during Diagnostic and Interventional Angiography." Cathet. Cardiovasc. Diagn., Vol. 19, Issue 2, pp. 123-128 (February 1990). Although the two IDS entries differ in the completeness of their citations, they reference the identical publication - the same journal, volume, page range, and year. The Examiner acknowledged the corrected IDS submission on 18 June 2026. Accordingly, the non-patent literature reference in question is of record and has been considered. Applicant respectfully requests that the Examiner reconsider this objection (Remarks, pages 9-10). Concern is withdrawn.
Examiner noted that the information disclosure statement filed April 10, 2026, fails to comply with 37 CFR 1.98(a)(2). Applicant provided copies of the indicated foreign patent documents. Concern is withdrawn.
Examiner objected to claims 1, 8, and 20-21. Applicant amended claims 1, 8, and 20-21. Objection is withdrawn.
Information Disclosure Statement
The information disclosure statement filed January 21, 2023, fails to comply with 37 CFR 1.98(a)(3)(i) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in 37 CFR 1.56(c) most knowledgeable about the content of the information, of each reference listed that is not in the English language. It has been placed in the application file, but the information referred to therein has not been considered:
No English translation has been provided for understanding of foreign patent document 6 (JP 5203971)
The information disclosure statement filed September 23, 2026, fails to comply with 37 CFR 1.98(a)(3)(i) because it does not include a concise explanation of the relevance, as it is presently understood by the individual designated in 37 CFR 1.56(c) most knowledgeable about the content of the information, of each reference listed that is not in the English language. It has been placed in the application file, but the information referred to therein has not been considered:
No English translation has been provided for understanding of foreign patent document 3 (JP 5203971)
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 1-4, 6-11, 13-16, 18, and 20-21 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
In regards to claim 1, lines 16-18 recite: wherein the calculating the estimated actual flow rate of the at least one medical fluid in the fluid path is based on… “a time lag”; however, such is new matter not described in the Specification. Claims 2-4 and 6-7 are rejected by virtue of being dependent upon claim 1.
In regards to claim 1, lines 20-21 recite: “wherein the time lag is compensated by applying a correction algorithm that accounts for system capacitance and injection parameters”; however, such is new matter not described in the Specification. Claims 2-4 and 6-7 are rejected by virtue of being dependent upon claim 1.
In regards to claim 1, lines 23-24 recite: “the time constant being derived based on system characteristics and injection conditions”; however, such is new matter not described in the Specification. Claims 2-4 and 6-7 are rejected by virtue of being dependent upon claim 1.
In regards to claim 8, lines 20-23 recite: wherein the at least one processor programmed or configured to calculate the estimated actual flow rate of the at least one medical fluid in the fluid path calculates the estimated actual flow rate of the at least one medical fluid based on… “a time lag”; however, such is new matter not described in the Specification. Claims 9-11 and 13-14 are rejected by virtue of being dependent upon claim 8.
In regards to claim 8, lines 25-26 recite: “wherein the time lag is compensated by applying a correction algorithm that accounts for system capacitance and injection parameters”; however, such is new matter not described in the Specification. Claims 9-11 and 13-14 are rejected by virtue of being dependent upon claim 8.
In regards to claim 8, lines 28-29 recite: “the time constant being derived based on system characteristics and injection conditions”; however, such is new matter not described in the Specification. Claims 9-11 and 13-14 are rejected by virtue of being dependent upon claim 8.
In regards to claim 15, lines 21-23 recite: wherein the one or more instructions to cause the at least one processor to calculate the estimated actual flow rate of the at least one medical fluid in the fluid path are based on… “a time lag”; however, such is new matter not described in the Specification. Claims 16, 18, and 20-21 are rejected by virtue of being dependent upon claim 15.
In regards to claim 15, lines 25-26 recite: “wherein the time lag is compensated by applying a correction algorithm that accounts for system capacitance and injection parameters”; however, such is new matter not described in the Specification. Claims 16, 18, and 20-21 are rejected by virtue of being dependent upon claim 15.
In regards to claim 15, lines 28-29 recite: “the time constant being derived based on system characteristics and injection conditions”; however, such is new matter not described in the Specification. Claims 16, 18, and 20-21 are rejected by virtue of being dependent upon claim 15.
Response to Arguments
Applicant's arguments filed September 23, 2026, have been fully considered but they are not persuasive:
In regards to claim 1, Applicant argued: Applicant believes the element "a time lag" is fully supported by the originally filed. For example, the originally filed PCT Application at paragraph [00102] references a "lag" when discussing FIG. 9, which plots commanded flow rate and actual measured flow rate over time. The discussion references "a lag" where the measured actual flow rate "lags" in time behind the commanded flow rate (i.e., a time lag). Paragraph [00102] further recites that the commanded flow rate may be programmed to reach 6 mL/sec withing 400 milliseconds after initiating the injection, while the actual flow rate may not reach the commanded flow rate of 6 mL/sec until 2-3 seconds after the injection begins. This is the "time lag" referred to in claim 1. Thus, Applicant believes that one of ordinary skill in the art would understand that the element "time lag" is fully supported by the original specification and Applicant submits that claim 1 fully satisfies the written description requirement with regard to element "time lag". Claims dependent from claim 1 also satisfy the written description requirement for at least these reasons. Withdrawal of this rejection of claims 1- 4, 6, and 7 under 35 U.S.C. § 112(a) is respectfully requested (Remarks, pages 9-10). Examiner disagrees. Specification (paragraph [00102]) recites “As may be appreciated from FIG. 9, the curve of the actual flow rate 720, for example as measured at the location of the air detector 200, may generally lag behind a curve of the commanded flow rate 730 because some of the fluid pressure is absorbed by system capacitance of components of the fluid injector system 100 instead of being converted in to kinetic fluid flow. The lag may be particularly noticeable during an initial rise time 732 of the commanded flow rate, which may be an approximately vertical portion of the commanded flow rate curve 730 where at least a portion of the pressure applied to the system is converted to system capacitance, due to, for example, pressurized swelling of system components, uptake of mechanical slack, and compression of one or more air bubbles in the fluid. Further, a lag may also be observed at the end of a fluid injection 734 where pressure from the mechanical components, for example the piston, is halted but release of system capacitance causes the fluid to flow”. However, Specification does not disclose wherein the calculating the estimated actual flow rate of the at least one medical fluid in the fluid path is based on… “a time lag” (i.e. “a time lag” is not disclosed to be used in the calculation of the estimated actual flow rate).
In regards to claim 1, Applicant argued: The Examiner notes that claim 1, lines 22-23 further references "wherein the time lag is compensated by applying a correction algorithm that accounts for system capacitance and injection parameters." As noted above, "time lag" is fully supported by the originally filed application. Discussion of the correction algorithm to correct the time lag between the commanded flow rate and the actual flow is discussed, for example, in paragraph [00103]- [00104] of the originally filed application. Thus, compensating for the time lag by applying a correction algorithm is fully supported by the filed application and the written description requirement for the claimed feature is satisfied for claim 1 and its dependent claims. Withdrawal of this rejection of claims 1-4, 6, and 7 under 35 U.S.C. § 112(a) is respectfully requested (Remarks, page 10). Examiner disagrees. Specification (paragraph [00102]) recites “As may be appreciated from FIG. 9, the curve of the actual flow rate 720, for example as measured at the location of the air detector 200, may generally lag behind a curve of the commanded flow rate 730 because some of the fluid pressure is absorbed by system capacitance of components of the fluid injector system 100 instead of being converted in to kinetic fluid flow. The lag may be particularly noticeable during an initial rise time 732 of the commanded flow rate, which may be an approximately vertical portion of the commanded flow rate curve 730 where at least a portion of the pressure applied to the system is converted to system capacitance, due to, for example, pressurized swelling of system components, uptake of mechanical slack, and compression of one or more air bubbles in the fluid. Further, a lag may also be observed at the end of a fluid injection 734 where pressure from the mechanical components, for example the piston, is halted but release of system capacitance causes the fluid to flow”. However, Specification does not disclose “wherein the time lag is compensated by applying a correction algorithm that accounts for system capacitance and injection parameters” (i.e. “a time lag” is not disclosed to be compensated by applying a correction algorithm).
In regards to claim 1, Applicant argued: The Examiner further asserts that claim 1, lines 25-26 and the recitation "the time constant being derived based on system characteristics and injection conditions" is not supported by the filed Specification. Applicant directs the Examiner's attention to paragraph[00103]-[00104] where first order time constant is discussed and selected to minimize error arising from injection parameters, system characteristics and conditions. Applicant believes that derivation of time constant "z" is fully supported by the original Specification and this feature of claim 1 and its dependent claims satisfies the written description requirement. Withdrawal of this rejection of claims 1-4, 6, and 7 under35 U.S.C. § 112(a) is respectfully requested (Remarks, page 10). Examiner disagrees. Specification (paragraphs [00103][00104]) recites: “To compensate for the effects of system capacitance on the actual flow rate within the fluid path, the at least one processor 904 may apply one or more correction algorithm to the commanded flow rate to estimate the actual flow rate. The correction algorithm may be derived from one or more equations and/or look-up table containing system and injection parameters stored in the memory 906 and/or storage component 908 accessible by the at least one processor 904. In some embodiments, the one or more correction algorithm may include an equation to reduce the processing power required to convert the commanded flow rate to an estimated actual flow rate. An example of the equation is shown in Equation 1: Equation 1: Actual flow rate = Commanded flow rate x (1 - e-t/τ) In Equation 1, "Actual flow rate" is the estimated or calculated flow rate taking into account injection parameters and system capacitance in milliliters per second (mL/s), "Commanded flow rate" is the programmed injection rate in mL/s (e.g. the flow rate defined by the curve 730 in FIG. 9), "t" is the time after the injection procedure has started in seconds, and "τ" is a first order time constant. According to various embodiments, "τ" may be determined prior to performing the injection procedure and/or may be stored in the memory 906 and/or the storage component 908 for access by the at least one processor 904 during the injection procedure. In particular, "τ" may be selected to minimize error relative to actual fluid flow rate between various injection procedures. Examples of injection parameters that may affect actual flow rate include, but are not limited to, syringe size and fluid volume, tubing diameter, position of plunger in syringe, syringe and tubing material, commanded flow rate, fluid viscosity, volume of air present, and the like. FIG. 10 illustrates a nonlimiting example of a graph showing the derivation of Equation 1 from an embodiment of an experimental injection procedure. Curve 740 is a normalization of actual flow rate over time for an experimental injection procedure having a relatively short rise time of the commanded fluid flow rate. Curve 742 is a normalization of actual flow rate over time for an experimental injection procedure having a relatively long rise time of the commanded fluid flow rate. Curve 744 represents the flow rate over time as calculated by Equation 1, with the value of "τ" optimized such that curve 744 falls approximately between curves 740 and 742. Thus, the error between curve 744 and curve 740 is approximately equal to the error between curve 744 and 742. By optimizing "τ" in this manner according to certain embodiments, a single value for "τ" may be used to provide a sufficiently accurate estimation of actual flow rate for a wide variety of commanded flow rates. As will be described herein, the at least one processor 904 may perform a calculation using the optimized value for "τ". Furthermore using a single optimized value of "τ" can significantly reduce the processing demands on the at least one processor 904 as Equation 1 may be repeatedly calculated in intervals of hundreds of milliseconds throughout the injection procedure and appropriate adjustments made. In some embodiments where available processing power is not of particular concern, the multiple values of "τ" corresponding to various positions of the pistons 103 within the syringes 132 may be used, and the at least one processor 904 may use a stored look-up table to select the appropriate value for "τ" during each calculation of Equation 1. Alternatively or in addition, in some embodiments, the at least one processor 904 may use other known parameters of the injection procedure and/or fluid injector system 100, such as the type of fluid injected, the catheter size, etc., to further select an appropriate "τ" value to enhance accuracy of the flow rate estimation”. However, Specification does not disclose “the time constant being derived based on system characteristics and injection conditions” (i.e. “the time constant” is not disclosed to be derived based on system characteristics and injection conditions).
In regards to claims 8 and 15, Applicant argued: Independent claim 8 and its dependent claims 9-11, 13, and 14 and independent claim 15 and its independent claims 16, 18, 20, and 21 are rejected for the same reasons as claim 1, i.e., lack of support for "a time lag," "wherein the time lag is compensated by applying a correction algorithm that accounts for system capacitance and injection parameters," and "the time constant being derived based on system characteristics and injection conditions." Applicant submits that these claims satisfy the written description requirements for at least the reasons set forth above with reference to paragraphs [00102]- [00104] as described for claim 1. Withdrawal of the rejections of claims 8-11, 13-16, 18, 20, and 21 under 35 U.S.C. § 112(a) is respectfully requested (Remarks, page 11). Examiner disagrees and maintains the rejection of claims 8 and 15 for the same reasons as provided above with respect to claim 1.
Conclusion
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHEFALI D PATEL whose telephone number is (571)270-3645. The examiner can normally be reached Monday-Friday 8:30am-4:30pm EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kevin C Sirmons can be reached at (571) 272-4965. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SHEFALI D PATEL/Primary Examiner, Art Unit 3783